These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33164519)

  • 21. Improved small molecule drug release from in situ forming poly(lactic-co-glycolic acid) scaffolds incorporating poly(β-amino ester) and hydroxyapatite microparticles.
    Fisher PD; Palomino P; Milbrandt TA; Hilt JZ; Puleo DA
    J Biomater Sci Polym Ed; 2014; 25(11):1174-93. PubMed ID: 24903524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninvasive characterization of in situ forming implant diffusivity using diffusion-weighted MRI.
    Hopkins KA; Vike N; Li X; Kennedy J; Simmons E; Rispoli J; Solorio L
    J Control Release; 2019 Sep; 309():289-301. PubMed ID: 31323243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of injection site on in situ implant formation and drug release in vivo.
    Patel RB; Solorio L; Wu H; Krupka T; Exner AA
    J Control Release; 2010 Nov; 147(3):350-8. PubMed ID: 20728486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accelerated in vitro release testing method for a long-acting peptide-PLGA formulation.
    Goel M; Leung D; Famili A; Chang D; Nayak P; Al-Sayah M
    Eur J Pharm Biopharm; 2021 Aug; 165():185-192. PubMed ID: 33992753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone.
    Stein S; Auel T; Kempin W; Bogdahn M; Weitschies W; Seidlitz A
    Eur J Pharm Biopharm; 2018 Jun; 127():270-278. PubMed ID: 29490233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
    Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA
    Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-Controlled Release of Poorly Water-Soluble Paliperidone Palmitate from Self-Assembled Albumin-Oleic Acid Nanoparticles in PLGA in situ Forming Implant.
    Yu Y; Ngo HV; Jin G; Tran PHL; Tran TTD; Nguyen VH; Park C; Lee BJ
    Int J Nanomedicine; 2021; 16():2819-2831. PubMed ID: 33888982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.
    Kelley RA; Ghaffari A; Wang Y; Choi S; Taylor JR; Hartman RR; Kompella UB
    J Ocul Pharmacol Ther; 2020 Jun; 36(5):290-297. PubMed ID: 32330403
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-Lasting
    Bazraee S; Mobedi H; Mashak A; Jamshidi A
    Curr Drug Deliv; 2022; 19(1):157-166. PubMed ID: 34139983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
    Sheshala R; Hong GC; Yee WP; Meka VS; Thakur RRS
    Drug Deliv Transl Res; 2019 Apr; 9(2):534-542. PubMed ID: 29484530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long lasting in-situ forming implant loaded with raloxifene HCl: An injectable delivery system for treatment of bone injuries.
    Elkasabgy NA; Abdel-Salam FS; Mahmoud AA; Basalious EB; Amer MS; Mostafa AA; Elkheshen SA
    Int J Pharm; 2019 Nov; 571():118703. PubMed ID: 31536761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
    Kranz H; Bodmeier R
    Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of PLGA
    Ibrahim TM; El-Megrab NA; El-Nahas HM
    Pharm Dev Technol; 2021 Sep; 26(7):709-728. PubMed ID: 34176433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.
    Patel RB; Carlson AN; Solorio L; Exner AA
    J Biomed Mater Res A; 2010 Aug; 94(2):476-84. PubMed ID: 20186771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel adapter method for in vitro release testing of in situ forming implants.
    Wang X; Bao Q; Suh MS; Kastellorizios M; Wang R; Burgess DJ
    Int J Pharm; 2022 Jun; 621():121777. PubMed ID: 35489601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant.
    Ravivarapu HB; Moyer KL; Dunn RL
    AAPS PharmSciTech; 2000 Feb; 1(1):E1. PubMed ID: 14727850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres.
    Andhariya JV; Jog R; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
    J Control Release; 2019 Aug; 308():1-13. PubMed ID: 31301338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D printed PLGA implants: How the filling density affects drug release.
    Bassand C; Siepmann F; Benabed L; Verin J; Freitag J; Charlon S; Soulestin J; Siepmann J
    J Control Release; 2023 Nov; 363():1-11. PubMed ID: 37714435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-situ forming PLGA implants for intraocular dexamethasone delivery.
    Bode C; Kranz H; Siepmann F; Siepmann J
    Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process.
    Kempe S; Metz H; Mäder K
    J Control Release; 2008 Sep; 130(3):220-5. PubMed ID: 18611421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.